Society for Immunotherapy of Cancer (SITC) on LinkedIn Nominate the

Sitc 2025 Ak132. Home SITC 2025 (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A. And it's worth remembering Shattuck Labs, whose own take on CD47 differs by the inclusion of a CD40L domain to activate macrophages; further data from early trials of SL-154 are due this year.

AK132 efficiently inhibits tumor growth in mice with subcutaneous MC38-hCD47hCLDN18.2 tumor. Make your mark at the largest cancer immunotherapy conference and exhibit at SITC''s 40th Anniversary Annual Meeting, hosted by the leading member-driven o

Home SITC 2025

(Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking. The Women in Cancer Immunotherapy Network (WIN) is a SITC initiative seeking to promote and elevate women in the cancer immunotherapy field SITC 2025 is held in Washington DC, United States, from 11/5/2025 to 11/5/2025 in Gaylord National Resort and Convention Center.

Global Immunotherapy Access Society for Immunotherapy of Cancer (SITC). (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking. 8, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926.HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47.

Register for SITC Winter School 2025 Society for Immunotherapy of. Results AK132 could bind to human CD47 and CLDN18.2 on CD47 + CLDN18.2 + cells, with same activity relative to its parental mAbs, AK117 (anti-CD47 mAb) and anti-CLDN18.2 AK132 showed ADCC, ADCP or CDC activity on CD47 + CLDN18.2+ tumor cells when compared with AK117